A method for efficient synthesis of epiinositol using a thermostable muscle inositol dehydrogenase mutant cascade system.
By using directed evolution mutants of squalinositol dehydrogenase and thermostable muscle inositol dehydrogenase, a two-step whole-cell catalytic method for synthesizing epiinositol from muscle inositol was developed. This method solves the environmental pollution and enzyme recognition problems associated with chemical synthesis, and achieves a highly efficient and low-cost biosynthetic method. The catalytic efficiency and yield of the mutant enzymes are significantly improved.
Patent Information
- Application Number
- CN202411801320.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-09
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2044-12-09
AI Technical Summary
The existing chemical synthesis of epiinositol has problems such as dangerous and unstable reaction reagents, significant environmental pollution, and high preparation costs. In addition, enzymes in biocatalytic methods have difficulty specifically recognizing different chiral compounds of inositol, resulting in no reported biosynthetic methods for epiinositol.
Using directed-evolution mutants of squalinositol dehydrogenase and thermostable muscle inositol dehydrogenase, a two-step whole-cell method was used to catalyze the synthesis of epiinositol from muscle inositol. This involved squalinositol dehydrogenase catalyzing the dehydrogenation of the C4 hydroxyl group to produce the intermediate 1L-epio-2-inosaccharide, and thermostable muscle inositol dehydrogenase catalyzing the hydrogenation of the C4 carbonyl group to produce epiinositol.
The biosynthesis of epiinositol, which is simple to operate, low in cost, and environmentally friendly, has been achieved. The catalytic efficiency of the mutant enzyme is improved, and the yield reaches 52.6%. No additional NADH is required, which has industrialization potential.
Smart Images

Figure CN119799803B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a method for the efficient synthesis of epiinositol from a thermostable muscle inositol dehydrogenase mutant cascade system, belonging to the field of biocatalysis engineering. Background Technology
[0002] Myoinositol is an important nutrient with various health benefits as a dietary supplement. Inositol exists in eight stereoisomers, including naturally occurring epi-inositol, allo-inositol, muco-inositol, neo-inositol, L-chiro-inositol, D-chiro-inositol, and scyllo-inositol, as well as cis-inositol, which has not been observed in nature. Epi-inositol, as one of these stereoisomers, also has value in food, health, and medicine. Studies have shown that daily intraperitoneal injection of epi-inositol in rats can reduce anxiety levels, and is more effective than inositol. 100 μM epi-inositol is equivalent to 100 nM insulin in promoting GLUT4-dependent glucose uptake in the L6 myotubules of rats.
[0003] The synthesis technology of epiinositol is currently limited to chemical synthesis, mainly through the catalytic reduction of epiinositol using sodium borohydride under alkaline conditions. However, the chemical synthesis method suffers from drawbacks such as hazardous and unstable reagents, significant environmental pollution, and high production costs, resulting in an extremely high market price for epiinositol, approximately 14,000 yuan per gram.
[0004] In recent years, with the development of synthetic biology technology, the biotransformation synthesis of inositol isomers has become a new research hotspot. Fujisawa et al. constructed an in vitro enzyme system for producing inositol from starch using four enzymes: maltodextrin phosphorylase (MalP), glucose-phosphomutase (PGM), inositol-3-phosphate synthase (MIPS), and inositol monophosphatase (IMPase). After 7 hours of reaction, 2.9 g of inositol could be produced from 2.9 g of starch, with a molar conversion rate of approximately 96%. Paul et al. achieved the conversion from glucose to squalinositol by modifying Corynebacterium glutamicum, catalyzing the synthesis of 1.8 g / L squalinositol from a 20 g / L glucose substrate within 72 hours. Ji et al. co-expressed inositol isomerase IolI2 and inositol dehydrogenase IolG in Corynebacterium glutamicum, obtaining a squalinositol-producing strain, DCI-7, which could generate 6.96 g / L D-chiral inositol in the presence of 40 g / L inositol.
[0005] Currently reported myoinositol 2-dehydrogenases (EC 1.1.1.18, abbreviated as IDH) almost exclusively catalyze the dehydrogenation of myoinositol at the C2 position to yield squalene, while the more common squalene dehydrogenase (SCY1.1.1.370, abbreviated as sIDH) catalyzes the synthesis of squalene from squalene. Unlike common squalene and D-chiral inositol synthesis methods, the synthesis of epi-inositol from myoinositol requires dehydrogenation at the C4 position followed by hydrogenation to achieve chiral reversal. Furthermore, due to the highly symmetrical structures of both the substrate and product, enzymes often struggle to specifically recognize each other during catalysis. Therefore, the synthesis of different chiral compounds of inositol has always been a significant challenge in the field of biocatalysis. To date, no biosynthetic methods for epi-inositol have been reported. Therefore, there is an urgent need to develop a simple, low-pollution, and low-cost biosynthetic method for epi-inositol. Summary of the Invention
[0006] To address the challenges in the biosynthesis of epiinositol, this invention provides a two-step whole-cell catalytic method for the synthesis of epiinositol from muscle inositol: The first step utilizes squalinositol dehydrogenase (sIDH) to catalyze the dehydrogenation of the C4 hydroxyl group, producing the intermediate 1L-epio-2-inosaccharide; the second step uses thermostable myoinositol dehydrogenase (IDH) to catalyze the hydrogenation of the C4 carbonyl group, producing epiinositol. Based on sequence conservation structural analysis and virtual mutation screening, directed evolution of these two enzymes yielded mutants with higher catalytic efficiency. This invention offers advantages such as simple production process, low production cost, and environmental friendliness, laying a solid foundation for the industrial-scale preparation of epiinositol.
[0007] To solve the above-mentioned technical problems, the present invention adopts the following technical solution:
[0008] This invention provides a method for preparing epiinositol, wherein the method comprises using squalene dehydrogenase or genetically engineered bacteria expressing squalene dehydrogenase to catalyze the synthesis of 1L-epio-2-inosaccharide from muscle inositol in whole cells; then adding thermostable muscle inositol dehydrogenase or genetically engineered bacteria expressing thermostable muscle inositol dehydrogenase to catalyze the synthesis of epiinositol from the 1L-epio-2-inosaccharide in whole cells.
[0009] In one embodiment of the present invention, the method is as follows:
[0010] (1) Engineered bacteria and / or mutants that express squalinositol dehydrogenase and thermostable muscle inositol dehydrogenase, respectively;
[0011] (2) Ferment the engineered bacteria and / or mutants constructed in step (1) to obtain whole cells;
[0012] (3) The heat-resistant muscle inositol dehydrogenase obtained in step (2) is subjected to cell membrane permeability treatment to obtain permeable whole cells;
[0013] (4) Using the whole-cell catalytic myo-inositol obtained in step (2) to synthesize 1L-epi-2-inosose from myo-inositol;
[0014] Epi-inositol was synthesized from 1L-epi-2-inosose using permeable whole cells expressing thermostable muscle inositol dehydrogenase or whole cell lysates expressing thermostable muscle inositol dehydrogenase obtained in step (3).
[0015] In one embodiment of the present invention, the catalytic pathway comprises: squalene dehydrogenase in NAD+... + In the presence of NADH, the substrate muscle inositol is oxidized to the intermediate 1L-epio-2-glycosylation; the intermediate 1L-epio-2-glycosylation is then reduced to the product epiinositol by thermostable muscle inositol dehydrogenase in the presence of NADH. Figure 2 As shown. In the catalytic pathway of this invention, the required NADH comes from squalinositol dehydrogenase in the NAD+ pathway. + The process of oxidizing the substrate muscle inositol to the intermediate 1L-epio-2-inosaccharide in the presence of NADH is described in the present invention. That is, the method of the present invention does not include the step of adding NADH.
[0016] In one embodiment of the present invention, in step (1), the engineered bacteria comprises a vector expressing squalinositol dehydrogenase or a vector expressing thermostable muscle inositol dehydrogenase.
[0017] Those skilled in the art will understand that the carriers and engineered bacteria involved in this invention can be prepared using conventional methods known in the art.
[0018] In one embodiment of the present invention, according to the present invention, in step (1), the squalene dehydrogenase is an enzyme having the function of oxidizing myo-inositol to 1L-epi-2-inosose and / or reducing 1L-epi-2-inosose to myo-inositol; more preferably, the squalene dehydrogenase is derived from a Gfo / Idh / MocA family protein, such as a squalene dehydrogenase derived from Paracoccus caveernae, Paracoccus kondratievae, or Roseibium suaedae; more preferably, the squalene dehydrogenase is derived from Paracoccus kondratievae; or the amino acid sequence of the squalene dehydrogenase is derived from Paracoccus The squalene dehydrogenase of kondratievae has at least 70%, preferably at least 80%, more preferably at least 90%, and most preferably at least 95% identity.
[0019] In one embodiment of the present invention, according to the present invention, in step (1), the thermostable muscle inositol dehydrogenase refers to an enzyme that has the function of reducing 1L-epi-2-inosose to epi-inositol and / or oxidizing epi-inositol to 1L-epi-2-inosose at temperatures above 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, or 80°C; more preferably, the thermostable muscle inositol dehydrogenase is derived from Gfo / Idh / MocA family proteins, such as those derived from Laceyella putida, Geobacillus thermoleovorans, and Parageobacillus thermoglucosidase. Thermostable muscle inositol dehydrogenase of *Geobacillus thermoleovorans*; more preferably, the thermostable muscle inositol dehydrogenase is derived from *Geobacillus thermoleovorans*; or the amino acid sequence of the thermostable muscle inositol dehydrogenase has at least 70%, preferably at least 80%, more preferably at least 90%, and most preferably at least 95% identity with the thermostable muscle inositol dehydrogenase derived from *Geobacillus thermoleovorans*.
[0020] In one embodiment of the present invention, according to the present invention, in step (1), the squalene dehydrogenase mutant is obtained by mutating the amino acid at position 261 and / or position 322 of the squalene dehydrogenase as shown in SEQ ID NO.1; more preferably, the squalene dehydrogenase mutant is obtained by mutating the amino acid at position 261 and position 322.
[0021] Most preferably, the squalene dehydrogenase mutant is obtained by mutating cysteine at position 261 of the squalene dehydrogenase shown in SEQ ID NO.1 to arginine or lysine; or the squalene dehydrogenase mutant is obtained by mutating phenylalanine at position 322 of the squalene dehydrogenase shown in SEQ ID NO.1 to threonine; or the squalene dehydrogenase shown in SEQ ID NO.1 is obtained by mutating cysteine at position 261 to arginine and simultaneously mutating phenylalanine at position 322 to threonine.
[0022] In one embodiment of the present invention, according to the present invention, in step (1), the thermostable muscle inositol dehydrogenase mutant is obtained by mutating the amino acid at position 177 of the thermostable muscle inositol dehydrogenase as shown in SEQ ID NO.2.
[0023] Most preferably, the thermostable muscle inositol dehydrogenase mutant is obtained by mutating phenylalanine at position 177 of the thermostable muscle inositol dehydrogenase as shown in SEQ ID NO.2 to lysine or glutamic acid.
[0024] In one embodiment of the present invention, in step (2), the preparation of the whole cells is carried out using methods known in the art. Fermentation can be performed using any culture medium suitable for the expression of exogenous proteins, including but not limited to LB medium, TB medium, etc.
[0025] In one embodiment of the present invention, in step (3), the cell membrane permeability treatment includes, but is not limited to, heat treatment. Preferably, the cell membrane permeability treatment is heat treatment. The purpose of permeability treatment of the cell membrane is to enable extracellular muscle inositol to pass through the cell membrane into the cell.
[0026] In one embodiment of the present invention, the reaction conditions for the whole cell catalysis of the 1L-epio-2-inosaccharide are as follows: the whole cell is heat-treated before the reaction is carried out; the heat treatment conditions are: the heat treatment temperature is 50-70°C; more preferably, the heat treatment temperature is 55-70°C; more preferably, the heat treatment temperature is 60-65°C; and most preferably, the heat treatment temperature is 65°C.
[0027] The heat treatment time is 10 to 30 minutes; more preferably, the heat treatment time is 20 to 30 minutes; most preferably, the heat treatment time is 25 minutes.
[0028] In one embodiment of the present invention, the cell concentration of the heat treatment is 10-100 g / L; more preferably, the cell concentration of the heat treatment is 20-80 g / L; more preferably, the cell concentration of the heat treatment is 30-60 g / L; and most preferably, the cell concentration of the heat treatment is 40 g / L.
[0029] In one embodiment of the present invention, the heat treatment can be performed in a buffer-free system or a buffer system; preferably, the heat treatment is performed in a buffer system, wherein the buffer can be HEPES buffer, phosphate buffer, Tris buffer, acetate buffer, etc.
[0030] In one embodiment of the present invention, according to the present invention, in step (4), the reaction system for preparing 1L-epi-2-inositol from muscle inositol using squalene dehydrogenase catalyzed by squalene dehydrogenase is as follows:
[0031] The concentration of the substrate muscle inositol is 1–100 mM, NAD... + The concentration of the substrate is 1–100 mM, and the total amount added to the whole cells is 10–100 g / L; preferably, the concentration of the substrate muscle inositol is 10–80 mM, and the total amount added to the whole cells is 30–90 g / L; more preferably, the concentration of the substrate muscle inositol is 15–60 mM, and the NAD+ concentration is 10–80 mM. + The concentration of NAD+ is 15–60 mM, and the total amount added to whole cells is 40–80 g / L; most preferably, the concentration of the substrate muscle inositol is 20 mM. + The concentration was 20 mM, and the total amount of whole cells added was 80 g / L.
[0032] The reaction conditions for catalytic preparation of 1 L-epi-2-inosaccharide from muscle inositol are as follows: reaction at pH 6.0–10.0 and 20–50 °C for 2–24 h; preferably, reaction at pH 8.0–9.5 and 25–40 °C for 6–14 h; and most preferably, reaction at pH 9.5 and 28 °C for 12 h.
[0033] In one embodiment of the present invention, according to the present invention, in step (4), the reaction system for preparing epi-inositol from 1L-epio-2-inositol using thermostable muscle inositol dehydrogenase catalyzed by:
[0034] The concentration of substrate 1L-epi-2-inositose is 1–100 mM, Zn 2+ The addition amount is 0.1–5 mM, and the addition amount of whole cells is 10–100 g / L; preferably, the concentration of substrate 1 L-epio-2-inositose is 10–80 mM, Zn2+ The addition amount is 0.5–4 mM, and the addition amount to whole cells is 20–80 g / L; more preferably, the concentration of substrate 1 L-epio-2-inositose is 20–60 mM, Zn 2+ The addition amount is 1-3 mM, and the whole cell addition amount is 30-60 g / L; most preferably, the concentration of substrate 1 L-epio-2-inositose is 40 mM, Zn 2+ The amount added was 1 mM, and the amount of whole cells added was 40 g / L.
[0035] The reaction conditions for catalytic preparation of epiinositol from 1 L-epio-2-inositose are as follows: reaction at pH 6.0–10.0 and 35–70 °C for 2–24 h; preferably, reaction at pH 6.5–8.0 and 40–60 °C for 8–16 h; and most preferably, reaction at pH 7.5 and 50 °C for 14 h.
[0036] In one embodiment of the present invention, the catalytic reaction can be carried out in a buffer-free system or a buffer system; preferably, it can be carried out in a buffer system, wherein the buffer is HEPES buffer, phosphate buffer, Tris buffer, acetate buffer, etc. Phosphate buffer, for example, is sodium phosphate buffer, potassium phosphate buffer, etc.
[0037] In one embodiment of the present invention, according to the present invention, in step (4), the reaction conditions for the two-step catalytic preparation of epi-inositol from muscle inositol are as follows: after the reaction for the preparation of 1L-epio-2-inosaccharide from muscle inositol is completed, the pH of the reaction system is adjusted to 7.5, and then the whole-cell thermostable muscle inositol dehydrogenase and Zn are directly added to the reaction system. 2+ After mixing, the cells were heat-treated and reacted at pH 7.5 and 50°C for 14 hours.
[0038] This invention provides a squalene dehydrogenase mutant, which is obtained by mutating the 261st amino acid in the amino acid sequence shown in SEQ ID NO.1 to arginine, and is named C261R.
[0039] Alternatively, the squalinositol dehydrogenase mutant is obtained by mutating phenylalanine at position 322 of the squalinositol dehydrogenase, as shown in SEQ ID NO.1, to threonine, and is named F322T.
[0040] Alternatively, the squalinositol dehydrogenase mutant is obtained by mutating cysteine at position 261 of the squalinositol dehydrogenase as shown in SEQ ID NO.1 to arginine, and simultaneously mutating phenylalanine at position 322 to threonine, and is named C261R / F322T.
[0041] The parental enzyme sequence (SEQ ID NO.1) of the squalinositol dehydrogenase mutant is as follows:
[0042] MTATQKSLGVALIGTGFMGKCHAMAWRNLATAFGGMPPRLEVLADTPAERAAELASAFGFARGTGDWRAAVTDPAVDVVSITTPNGMHREMAALAAGKHVWLEKPMALTVEDAEAMETAARAAGRVTILGYNYTRSPAFRAAADLVAQGAIGRPIHFRGVYDEDYMADPELPWSWRLTRAEGGL GALGDLGCHLVSVMLALMGPVARVQAQMDTVVTERPHQGGTATVENEDQAQALIRFASGASGEFSCSRVARGYRCRLAWEVQGTEGTLRFDQERMNELWLYQPGQAETDGFRRILTGPAQPGFAAFCPAAGHNFGFNEQKVVEAEMLRQAIAGGIPAWPDFTAGLTIERIIHGMARSARTGQPVLF
[0043] The base sequence (SEQ ID NO.3) encoding the parental enzyme of the squalinositol dehydrogenase mutant is as follows:
[0044]
[0045] The base sequence encoding the squalene dehydrogenase mutant C261R / F322T (SEQ ID NO.5):
[0046]
[0047] This invention provides a thermostable muscle inositol dehydrogenase mutant, which is obtained by mutating the 177th amino acid of the amino acid sequence shown in SEQ ID NO.2 to lysine or glutamic acid, and is named F177K or F177E.
[0048] The parental enzyme sequence (SEQ ID NO.2) of the thermostable muscle inositol dehydrogenase mutant is as follows:
[0049] MTRVKVGILGAGGIAKVHTSILKKDERVQIIGVADIVEERAASLAKEAGEAKAVKSLEELFDLGVDAVYVTTPNTMHVEPVLKCLENNVHVFSEKPMATSLEGAEQIRQAAERSKAIYNLGMNRRYASVYKRVKELIDSGEVTPYLAHVKMNRGELLNPPWTANPKV TGGFLYETPFHLMDLCRYLFGEVQTVYCEAKQNISTEELDTFAIMMTFVSGTIVNFVTYAHAGWSFPFESLEVYGKYSTVATQELEKVMYAPGLQQAAQIYDFYQLSIEEKWGYKEEDRLFIDAIIHGAKPPVTAEDGFRSIQLLEAIYESAKTGKMIDFRQTALSK
[0050] The base sequence (SEQ ID NO.4) encoding the parental enzyme of the thermostable muscle inositol dehydrogenase mutant is as follows:
[0051]
[0052] The base sequence (SEQ ID NO.6) encoding the thermostable muscle inositol dehydrogenase mutant F177K is:
[0053]
[0054] In one embodiment of the present invention, the catalytic efficiency of the mutant is based on myo-inositol or 1L-epi-2-inosose as substrates and NAD+. + Alternatively, NADH can be used as a cofactor in the reaction, and the change in absorbance at 340 nm is measured using a microplate reader. One unit of enzyme activity (U) is defined as the ability to catalyze the oxidation of 1 μmol of NADH to NAD per minute under the measurement conditions. + The amount of enzyme.
[0055] In one embodiment of the present invention, the vector expressing squalinositol dehydrogenase includes a promoter, a squalinositol dehydrogenase gene, and a terminator; the vector expressing thermostable muscle inositol dehydrogenase includes a promoter, a thermostable muscle inositol dehydrogenase gene, and a terminator.
[0056] Those skilled in the art will understand that various expression vectors known in the art can be used in this invention, including but not limited to the pET series, pGEX series, pACYCDuet-1, pRSFDuet-1, etc. Preferably, the vector is pET-21a(+) or pET-28a(+).
[0057] Those skilled in the art will understand that various host cells known in the art can be used in this invention, including but not limited to Escherichia coli, Pichia pastoris, Saccharomyces cerevisiae, and Bacillus subtilis. Preferably, the host bacterium is Escherichia coli BL21(DE3).
[0058] Those skilled in the art will understand that various promoters known in the art can be used as promoters for this invention, including but not limited to the T7 promoter, lac promoter, tac promoter, trc promoter, PR promoter, etc. Preferably, the promoter is the T7 promoter.
[0059] Those skilled in the art will understand that various terminators known in the art can be used as terminators for this invention, including but not limited to the T7 terminator, the rrnB T1 terminator, and the rrnB T2 terminator. Preferably, the terminator is the T7 terminator.
[0060] The present invention provides a gene encoding the above-mentioned squalinositol dehydrogenase mutant or the above-mentioned heat-resistant muscle inositol dehydrogenase mutant.
[0061] The present invention also provides a recombinant vector carrying the above-mentioned genes.
[0062] The present invention also provides a recombinant cell that expresses the above-mentioned mutant, carries the above-mentioned gene, or carries the above-mentioned recombinant vector.
[0063] In one embodiment of the present invention, the recombinant cells are bacteria or fungi as host cells.
[0064] This invention relates to the above-mentioned vectors for expressing squalinositol dehydrogenase and vectors for expressing thermostable muscle inositol dehydrogenase.
[0065] This invention relates to engineered bacteria and mutants expressing squalinositol dehydrogenase and engineered bacteria and mutants expressing thermostable muscle inositol dehydrogenase.
[0066] According to the present invention, the engineered bacteria and mutants expressing squalinositol dehydrogenase contain a vector expressing squalinositol dehydrogenase; the engineered bacteria and mutants expressing thermostable muscle inositol dehydrogenase contain a vector expressing thermostable muscle inositol dehydrogenase.
[0067] This invention provides a method for improving the substrate affinity and catalytic efficiency of squalinositol dehydrogenase, wherein the method involves mutating cysteine at position 261 of the squalinositol dehydrogenase, as shown in SEQ ID NO.1, to arginine;
[0068] Alternatively, the phenylalanine at position 322 of the squalinositol dehydrogenase, as shown in SEQ ID NO.1, may be mutated to threonine;
[0069] Alternatively, the cysteine at position 261 of the squalene dehydrogenase, as shown in SEQ ID NO.1, may be mutated to arginine, and the phenylalanine at position 322 may be mutated to threonine.
[0070] This invention provides a method for improving the substrate affinity and catalytic efficiency of thermostable muscle inositol dehydrogenase, wherein the method comprises:
[0071] The phenylalanine at position 177 of the thermostable muscle inositol dehydrogenase, as shown in SEQ ID NO.2, is mutated to lysine or glutamic acid.
[0072] The present invention also provides the application of the above-mentioned squalinositol dehydrogenase mutant, or the gene encoding the above-mentioned squalinositol dehydrogenase mutant, or the recombinant vector carrying the above-mentioned squalinositol dehydrogenase mutant, or the recombinant cell expressing the above-mentioned squalinositol dehydrogenase mutant, or the above-mentioned method for improving substrate affinity and catalytic efficiency of squalinositol dehydrogenase in the preparation of 1L-epio-2-inosaccharide or products containing 1L-epio-2-inosaccharide.
[0073] The present invention also provides the application of the above-mentioned thermostable muscle inositol dehydrogenase mutant, or the gene encoding the above-mentioned thermostable muscle inositol dehydrogenase mutant, or the recombinant vector carrying the above-mentioned thermostable muscle inositol dehydrogenase mutant, or the recombinant cell expressing the above-mentioned thermostable muscle inositol dehydrogenase mutant, or the above-mentioned method for improving the substrate affinity and catalytic efficiency of thermostable muscle inositol dehydrogenase in the preparation of epiinositol or products containing epiinositol.
[0074] The present invention also provides the application of the above-mentioned method for preparing epiinositol, or the above-mentioned squalinositol dehydrogenase mutant, thermostable muscle inositol dehydrogenase mutant, or the above-mentioned gene, or the above-mentioned recombinant vector, or the above-mentioned recombinant cell, or the above-mentioned method for improving enzyme substrate affinity and catalytic efficiency in the preparation of epiinositol or products containing epiinositol.
[0075] Beneficial effects
[0076] (1) This invention is the first to use biosynthesis to prepare epi-inositol using muscle inositol as a substrate. Compared with chemical methods, this method has the advantages of simple operation, mild reaction conditions, high efficiency, low cost, and green environmental protection.
[0077] (2) Unlike enzymes commonly used to synthesize squalinositol and D-chiral inositol, this invention provides a squalinositol dehydrogenase that can catalyze the dehydrogenation of muscle inositol at the C4 position, thus solving the problem of enzyme regioselectivity in the biosynthesis of epi-inositol.
[0078] (3) This invention is the first to utilize a two-step method of whole cells expressing squalene dehydrogenase and whole cells expressing thermostable muscle inositol dehydrogenase to synthesize epiinositol from muscle inositol, and develops a simple and easy-to-scale new method for preparing epiinositol.
[0079] (4) This invention provides a mutant of squalinositol dehydrogenase and a mutant of thermostable muscle inositol dehydrogenase, respectively. The catalytic efficiency (kJ) of the squalinositol dehydrogenase mutant is... cat / K m The yield of 1 L-epi-2-inosose was 3.2 times that of the wild type, and the yield of 1 L-epi-2-inosose was 4.4 times that of the wild type; the catalytic efficiency (kJ) of the thermostable muscle inositol dehydrogenase mutant was 3.2 times that of the wild type. cat / K m The yield of epi-inositol is 1.7 times that of the wild type, and the yield of epi-inositol is 5.2 times that of the wild type.
[0080] (5) This invention optimized the reaction conditions for both the mutant squalinositol dehydrogenase and the thermostable muscle inositol dehydrogenase, exploring the optimal reaction temperature, pH, cell quantity, substrate quantity, and reaction time. In the optimized two-step catalytic reaction of muscle inositol to epiinositol using the dual-enzyme mutant, the total yield of epiinositol was 52.6%.
[0081] (6) This invention does not require the addition of NADH, which greatly reduces production costs and has important industrial application value. Attached Figure Description
[0082] Figure 1 Chemical structures of muscle inositol, 1L-epio-2-inosaccharide, and epiinositol.
[0083] Figure 2 Schematic diagram of whole-cell catalysis for the production of epiinositol from muscle inositol. myo-inositol: muscle inositol; epi-inositol: squalene; 1L-epi-2-inosose: 1L-epi-2-inosose; sIDH: squalene dehydrogenase; IDH: muscle inositol dehydrogenase.
[0084] Figure 3 : Initial yield of the enzyme reaction; where A is the initial yield of squalene dehydrogenase from different sources catalyzing the conversion of muscle inositol to 1L-epio-2-inosaccharide; B is the initial yield of thermostable muscle inositol dehydrogenase from different sources catalyzing the conversion of 1L-epio-2-inosaccharide to epiinositol.
[0085] Figure 4 : This is a molecular docking map of the substrate and enzyme; where A represents myo-inositol in the PksIDH binding pocket. A represents the amino acid residues within; B represents the binding of myo-inositol in the PksIDH binding pocket; C represents the binding of 1L-epi-2-inosose in the GtIDH binding pocket. The amino acid residues within; D represents the binding status of 1L-epi-2-inosose in the GtIDH binding pocket.
[0086] Figure 5 Virtual screening of mutation sites; where A is the PksIDH binding pocket in myo-inositol The binding energy change of semi-conserved amino acids in the GkIDH binding pocket during virtual saturation mutation; B represents the binding energy change of 1L-epi-2-inosose in the GkIDH binding pocket. The binding energy change when semi-conserved amino acids undergo virtual saturation mutations.
[0087] Figure 6 : HPLC chromatograms of the products; where A is the HPLC chromatogram of 1L-epio-2-inositol and B is the HPLC chromatogram of epiinositol.
[0088] Figure 7 SDS-PAGE analysis of recombinant engineered bacteria E. coli BL21 / PksIDH-C261R / F322T and E. coli BL21 / GtIDH-F177K; M, protein marker; 1, E. coli BL21 / PksIDH-C261R / F322T; 2, E. coli BL21 / GtIDH-F177K.
[0089] Figure 8The yield of 1L-epio-2-inosaccharide synthesized under different conditions; where A, E, and E represent the yield changes of intermediate 1L-epio-2-inosaccharide under different pH, reaction temperature, cell mass, substrate amount, and reaction time, respectively.
[0090] Figure 9 The yield of epiinositol synthesized under different conditions; where A and G represent different heat treatment conditions, reaction temperature, pH, cell mass, substrate mass, and Zn content, respectively. 2+ Changes in the yield of epiinositol under different addition amounts and reaction times. Detailed Implementation
[0091] To further illustrate the technical means and effects of this invention, specific embodiments are provided below to further explain the technical solution of this invention. However, it should be understood that the embodiments are merely exemplary and do not constitute any limitation on the scope of this invention. Those skilled in the art should understand that modifications or substitutions can be made to the details and form of the technical solution of this invention without departing from the spirit and scope of this invention, but all such modifications or substitutions fall within the protection scope of this invention.
[0092] Technical terms
[0093] Expression: The term “expression” includes any step involving the production of squalinositol dehydrogenase and thermostable muscle inositol dehydrogenase, including but not limited to transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
[0094] Expression vector: The term "expression vector" refers to a straight or circular DNA molecule containing a polynucleotide encoding the squalinositol dehydrogenase and the thermostable muscle inositol dehydrogenase of the present invention and operatively linked to a control sequence provided for their expression.
[0095] Host cell: The term "host cell" refers to any cell type that is readily transformed, transfected, transduced, etc., using nucleic acid constructs or expression vectors containing the polynucleotides of the present invention. Host cells can be any cell type useful in the production of squalene dehydrogenase and thermostable muscle inositol dehydrogenase, such as prokaryotic or eukaryotic cells. Prokaryotic host cells can be any Gram-positive or Gram-negative bacteria. Gram-positive bacteria include, but are not limited to: Bacillus, Clostridium, Enterococcus, Geobacillus, Lactobacillus, Lactococcus, Oceanic Bacillus, Staphylococcus, Streptococcus, and Streptomyces. Gram-negative bacteria include, but are not limited to, Campylobacter, Escherichia coli, Flavobacterium, Fusobacterium, Helicobacter, Mycobacterium, Neisseria, Pseudomonas, Salmonella, and Ureaplasma. Host cells can also be eukaryotic, such as mammalian, insect, plant, or fungal cells.
[0096] The culture media involved in the following examples are as follows:
[0097] LB liquid medium (g / L): peptone 10, yeast extract 5, sodium chloride 10, natural pH.
[0098] The detection methods involved in the following embodiments are as follows:
[0099] Detection of squalinositol dehydrogenase activity:
[0100] The enzyme activity of squalinositol dehydrogenase oxidizing myo-inositol was measured at 30℃ by determining the rate of change in absorbance of NADH at 340 nm. The enzyme activity assay system consisted of a 200 μL reaction volume, with 5 mM NAD+ added to 20 mM Tris-HCl buffer (pH 7.5). + Incubate with 50 mM myo-inositol in a 30°C metal bath for 3 min, then add 20 μL of a suitable concentration of purified enzyme, and scan the absorbance at 340 nm using a Bio-Tek Cytation 5 multi-functional cell imaging detection system.
[0101] Enzyme activity is defined as the ability of an enzyme to catalyze 1 μmol of NAD per minute under the conditions described above. + The amount of enzyme that reduces NADH is defined as one unit (U).
[0102] The formula for calculating enzyme activity is: Enzyme activity (U) = EW × V × 10 3 / (6220×0.625);
[0103] The formula for calculating specific activity is: Specific activity (U / mg) = Enzyme activity (U) / Protein content (mg);
[0104] Wherein, EW: change in absorbance at 340 nm within 1 min; V: volume of reaction solution (mL); 6220: molar extinction coefficient (L / mol / cm); 0.625: optical path distance (cm).
[0105] Determination of kinetic parameters:
[0106] According to the Michaelis equation v = V max ×[S] / K m +[S], calculate the enzyme's K for different substrates. m value.
[0107] Where, v: reaction rate (U / mg); V max [S]: Maximum reaction rate (U / mg); [S]: Substrate concentration (mM); K m The reaction rate v reaches half of 1 / 2V. max The substrate concentration at that time.
[0108] When the substrate concentration is saturated, k cat =V max / Et, calculate k cat value.
[0109] Among them, V max : Maximum reaction rate; Et: Enzyme concentration.
[0110] Dynamic parameter determination:
[0111] The total reaction volume was 200 μL. 20 mM Tris-HCl buffer (pH 7.5) and 5 mM NAD+ were added. + The temperature was maintained at 30℃ for 3 min, and 20 μL of a suitable concentration of pure enzyme was added. Specific enzyme activity was measured at different concentrations (1–100 mM) of the substrate myo-inositol. Enzyme kinetic curves were fitted using GraphPad software, with substrate concentration and specific enzyme activity as the x and y axes, respectively. A Michaelis-Menten equation model was selected for nonlinear fitting to obtain V0. max Value and K mThe value, k, is obtained through data conversion. cat Value and k cat / K m Values (Table 2).
[0112] Detection of the activity of thermostable muscle inositol dehydrogenase:
[0113] The enzyme activity of thermostable muscle inositol dehydrogenase in reducing 1L-epi-2-inosose was measured at 45℃ by determining the rate of change in absorbance of NADH at 340 nm. The enzyme activity assay system consisted of a 200 μL reaction volume, in which 5 mM NADH and 50 mM 1L-epi-2-inosose were added to 20 mM Tris-HCl buffer (pH 7.5), and the mixture was incubated in a metal bath at 45℃ for 3 min. Then, 20 μL of a suitable concentration of purified enzyme was added, and the absorbance change at 340 nm was scanned using a Bio-Tek Cytation 5 multi-functional cell imaging system.
[0114] Enzyme activity is defined as the ability of an enzyme to oxidize 1 μmol of NADH to NAD per minute under the conditions described above. + The amount of enzyme is defined as one unit, U.
[0115] The formula for calculating enzyme activity is: Enzyme activity (U) = EW × V × 10 3 / (6220×0.625);
[0116] The formula for calculating specific activity is: Specific activity (U / mg) = Enzyme activity (U) / Protein content (mg);
[0117] Wherein, EW: change in absorbance at 340 nm within 1 min; V: volume of reaction solution (mL); 6220: molar extinction coefficient (L / mol / cm); 0.625: optical path distance (cm).
[0118] Determination of kinetic parameters:
[0119] According to the Michaelis equation v = V max ×[S] / K m +[S], calculate the enzyme's K for different substrates. m value.
[0120] Where, v: reaction rate (U / mg); V max [S]: Maximum reaction rate (U / mg); [S]: Substrate concentration (mM); K m The reaction rate v reaches half of 1 / 2V. max The substrate concentration at that time.
[0121] When the substrate concentration is saturated, k cat =V max / Et, calculate kcat value.
[0122] Among them, V max : Maximum reaction rate; Et: Enzyme concentration.
[0123] Dynamic parameter determination:
[0124] The total reaction volume was 200 μL. 20 mM Tris-HCl buffer (pH 7.5) and 5 mM NADH were added, and the mixture was incubated at 45 °C for 3 min. Then, 20 μL of purified enzyme at an appropriate concentration was added. The specific enzyme activity was measured at different concentrations (1–100 mM) of the substrate 1 L-epi-2-inosose. Enzyme kinetic curves were fitted using GraphPad software. Substrate concentration and specific enzyme activity were plotted on the x and y axes, respectively. A Michaelis-Menten equation model was used for nonlinear fitting to obtain V0. max Value and K m The value, k, is obtained through data conversion. cat Value and k cat / K m Values (Table 4).
[0125] 1L-Table-2-Detection of muscle glycogen production:
[0126] The reaction was carried out at 30℃ and 200 rpm for 12 h, and samples were then analyzed by high-performance liquid chromatography (HPLC). The HPLC detection conditions were as follows: Sepax HP-Amino column; mobile phase: acetonitrile / water (v:v, 80:20); flow rate: 1 mL / min; column temperature: 40℃; detector: UV detector, detection wavelength: 210 nm; injection volume: 10 μL. The HPLC chromatogram of 1 L-Table-2-inosaccharide is shown below. Figure 7 As shown in A in the diagram.
[0127] Detection of epiinositol production:
[0128] After heat treatment at 60℃ for 20 min, the sample was reacted at 45℃ and 200 rpm for 12 h, and then analyzed by high-performance liquid chromatography (HPLC). The HPLC detection conditions were as follows: Bio-Rad Aminex HPX-87H column; mobile phase: 5 mL H₂SO₄; flow rate: 0.5 mL / min; column temperature: 60℃; detector: differential detector; injection volume: 10 μL. The HPLC chromatogram of epiinositol is shown below. Figure 7 As shown in B in the diagram.
[0129] Preparation of whole cells of recombinant engineered bacteria involved in the following examples
[0130] (1) Preparation of whole cells of recombinant engineered squalinositol dehydrogenase
[0131] Recombinant engineered E. coli BL21 / PksIDH or its mutants were inoculated into LB liquid medium containing ampicillin in test tubes and cultured at 37°C with shaking for 8 hours. The cultured bacterial suspension from the LB liquid test tubes was then inoculated at a rate of 1% into LB liquid shake flask medium containing ampicillin and cultured at 37°C for another 2 hours. When the OD value reached 0.4–0.6, the temperature was lowered to 25°C, and IPTG was added for induction at a final concentration of 0.3 mM. Fourteen hours after induction, cells were collected using a refrigerated centrifuge at 8000 rpm for 10 minutes, the supernatant was discarded, and whole cells expressing squalene dehydrogenase were obtained.
[0132] (2) Preparation of whole cells of recombinant engineered bacteria containing heat-resistant muscle inositol dehydrogenase
[0133] Recombinant engineered E. coli BL21 / GtIDH or its mutants were inoculated into LB liquid medium containing kanamycin in test tubes and cultured at 37°C with shaking for 8 hours. The cultured bacterial suspension from the LB liquid test tubes was then inoculated at a rate of 1% into LB liquid shake flask medium containing kanamycin, and cultured at 37°C for another 2 hours. When the OD value reached 0.4–0.6, the temperature was lowered to 28°C, and IPTG was added to a final concentration of 0.5 mM to induce protein expression. Twelve hours after induction, cells were collected using a refrigerated centrifuge, centrifuged at 8000 × g for 10 min, and the supernatant was discarded to obtain whole cells expressing thermostable muscle inositol dehydrogenase.
[0134] Example 1: Discovery of squalinositol dehydrogenase and thermostable muscle inositol dehydrogenase and construction of recombinant engineered bacteria
[0135] The specific steps are as follows:
[0136] 1. Discovery of squalene dehydrogenase and construction of recombinant engineered bacteria
[0137] (1) Construction of genetically engineered bacteria
[0138] Squalene dehydrogenases derived from Paracoccus cavernae (NCBI ID: WP_377687665.1), Paracoccus kondratievae (NCBI ID: WP_152368211.1), Roseibium suaedae (NCBI ID: WP_073014975.1), Celeribacter baekdonensis (NCBI ID: WP_339692564.1), Sinirhodobacter populi (NCBI ID: WP_128233564.1), and Donghiocola were used to synthesize squalene dehydrogenases. Recombinant vectors were prepared by ligating squalene dehydrogenases from *E. eburneus* (NCBI ID: WP_092465240.1), *Jiellapacifica* (NCBI ID: WP_163463107.1), *Thalassospira lohafexi* (NCBI ID: WP_101299495.1), *Pannonibacter indicus* (NCBI ID: WP_055457068.1), and *Devosia marina* (NCBI ID: WP_157290965.1) onto the pET21a vector.
[0139] The prepared recombinant vectors were introduced into E. coli BL21(DE3) to prepare recombinant strains (gene synthesis and construction of recombinant engineered bacteria were completed by Sangon Biotech (Shanghai) Co., Ltd.).
[0140] (2) Enzyme screening Figures 3-4 )
[0141] The recombinant strains were inoculated into LB liquid culture medium containing ampicillin in test tubes and cultured at 37°C with shaking for 8 hours. The bacterial culture from the LB liquid test tubes was then inoculated into LB liquid shake flask culture medium containing ampicillin at a rate of 1% (v / v) and cultured at 37°C for another 2 hours. When the OD value reached 0.4–0.6, the temperature was lowered to 25°C, and IPTG was added for induction at a final concentration of 0.3 mM. After 14 hours of induction, the cells were collected using a low-temperature refrigerated centrifuge, centrifuged at 8000 × g for 10 min, and the supernatant was discarded to obtain whole cells expressing squalene dehydrogenase.
[0142] Reaction system: Resuspend 1 mL of reaction mixture (pH 7.5) in whole cells at a concentration of 30 g / L. The reaction mixture contains 20 mM NAD. + The reaction mixture was reacted with 20 mM myo-inositol (dissolved in 50 mM Tris-NaCl buffer) at 30 °C and 200 rpm for 12 hours. After the reaction was completed, the reaction mixture was heat-inactivated to terminate the enzyme activity.
[0143] The initial conversion rate at 20 mM muscle inositol was determined, and the results are as follows: Figure 3 As shown in Figure A, the squalene dehydrogenase (PksIDH) derived from Paracoccus kondratievae had the highest initial conversion rate (15.9%) among the screened enzymes, and was selected as the research object. The results show that not all sources of squalene dehydrogenase can be used to prepare 1L-epio-2-inosaccharide.
[0144] 2. Discovery of thermostable muscle inositol dehydrogenase and construction of recombinant engineered bacteria
[0145] (1) Construction of genetically engineered bacteria
[0146] Thermostable muscle inositol dehydrogenases derived from *Laceyella putida* (NCBI ID: WP_379863543.1), *Geobacillus thermoleovorans* (NCBI ID: WP_367164351.1), *Parageobacillus thermoglucosidasius* (NCBI ID: WP_064550463.1), *Anoxybacillus tepidamans* (NCBI ID: WP_183254894.1), and *Marinithermofilum abyssi* (NCBI ID: WP_229751859.1) were respectively used to extract thermostable muscle inositol dehydrogenases from *Laceyella putida* (NCBI ID: WP_379863543.1), *Geobacillus thermoleovorans* (NCBI ID: WP_367164351.1), *Parageobacillus thermoglucosidasius* (NCBI ID: WP_064550463.1), *Anoxybacillus tepidamans* (NCBI ID: WP_183254894.1), and *Marinithermofilum abyssi* (NCBI ID: WP_229751859.1). Thermostable muscle inositol dehydrogenases derived from *Toebii* (NCBI ID: WP_255265174.1), *Caldalkalibacillus mannanilyticus* (NCBI ID: WP_025027206.1), *Ectobacillus funiculus* (NCBI ID: MFC6605139.1), *Salifodinibacter halophilus* (NCBI ID: NNC22636.1), and *Acidobacteriota bacterium* (NCBI ID: MBI1748953.1) were ligated into the pET28a vector to prepare recombinant vectors.
[0147] The prepared recombinant vectors were introduced into E. coli BL21(DE3); recombinant strains were prepared (gene synthesis and construction of recombinant engineered bacteria were completed by Sangon Biotech (Shanghai) Co., Ltd.).
[0148] (2) Enzyme screening
[0149] Recombinant bacterial strains were picked and inoculated into LB liquid culture medium containing kanamycin in test tubes and cultured at 37°C with shaking for 8 hours. The bacterial culture from the LB liquid test tubes was then inoculated into LB liquid shake flask culture medium containing kanamycin at an inoculation rate of 1% (v / v) and cultured at 37°C for another 2 hours. When the OD value reached 0.4–0.6, the temperature was lowered to 28°C, and IPTG was added for induction at a final concentration of 0.5 mM. After 12 hours of induction, the cells were collected using a low-temperature refrigerated centrifuge. The cells were centrifuged at 8000 × g for 10 min, and the supernatant was discarded to obtain whole cells expressing thermostable muscle inositol dehydrogenase.
[0150] Reaction system: 1 mL of reaction mixture (pH 7.5) was added to whole cells at a concentration of 20 g / L for resuspension. The reaction mixture contained 10 mM NADH and 10 mM 1 L-epi-2-inosose (dissolved in 50 mM Tris-NaCl buffer). After heat treatment at 60 °C for 20 min, the reaction mixture was reacted at 45 °C and 200 rpm for 12 h. After the reaction was completed, the enzyme activity was terminated by heat inactivation of the reaction mixture.
[0151] The initial conversion rate at 20 mM 1 L-epio-2-kinose was determined, and the results are as follows: Figure 3 As shown in B, the thermostable muscle inositol dehydrogenase (GtIDH) from Geobaci1lus thermoleovorans exhibited the highest initial conversion rate (10.2%) among the screened enzymes, and this enzyme was selected as the research subject.
[0152] Example 2: Screening of squalinositol dehydrogenase mutants
[0153] The specific steps are as follows:
[0154] 1. Structural analysis of squalene dehydrogenase
[0155] By combining PksIDH with myo-inositol and cofactor NAD + Molecular docking was performed, and the results were as follows: Figure 5 As shown in A, several semi-conserved sites existing in the substrate-binding region, such as Y163, Y167, L192, R260, C261, and F322, were identified, and virtual mutations were performed on these semi-conserved sites.
[0156] 2. Virtual screening of squalene dehydrogenase mutation sites
[0157] By performing virtual saturation mutagenesis on the amino acid residues obtained from the screening in step 1, the results are as follows: Figure 6As shown in A, the binding energies of mutation sites C261 and F322 to the protein molecule show significant changes, proving that these three sites are key residues for binding to the substrate myo-inositol. These sites were selected as mutation sites for directed evolution.
[0158] (1) Directed evolution of squalinositol dehydrogenase mutants
[0159] The mutation hotspots C261 and F322 from step 2 were selected as mutation origins. Random mutations were then introduced at the corresponding sites via PCR using degenerate primers (NNK-MNN). The sequences of the degenerate primers (NNK-MNN) are shown in Table 1; where N represents a random one of the four nucleotides ATCG, K represents a random one of the two nucleotides GT, and M represents a random one of the two nucleotides AC.
[0160] Table 1: Primer design for squalinositol dehydrogenase mutant gene
[0161]
[0162] The PCR reaction mixture was as follows: 1 μL upstream primer, 1 μL downstream primer, 1 μL template plasmid, 5 μL 2×Primstar, and 2 μL ddH2O. The pre-denaturation temperature was 98℃ for 30 s, the denaturation temperature was 98℃ for 15 s, the annealing temperature was 55℃ for 30 s, and the extension temperature was 72℃ for 80 s.
[0163] (2) The recombinant expression vector containing wild type and the recombinant expression vector with random mutation were transformed into E.coli BL21(DE3) competent cells to prepare recombinant expression strains (the synthesis of genes and the construction of recombinant engineered bacteria were completed by Sangon Biotech (Shanghai) Co., Ltd.).
[0164] First, the monoclonal recombinant strains with introduced random mutations were cultured and induced to express the enzyme in 96-well plates, with the wild-type strain as a control (culture conditions were the same as for whole-cell preparation in Example 1). After centrifugation and removal of the supernatant, 1 mL of the reaction mixture (pH 7.5) was added in situ for resuspending. The reaction mixture contained 10 mM NADH and 10 mM myo-inositol (dissolved in 50 mM Tris-NaCl buffer), and the reaction was carried out at 30 °C and 200 rpm for 12 hours. After the reaction, the reaction mixture was heat-inactivated to terminate the enzyme activity.
[0165] Subsequently, the absorbance was measured at 340 nm using a BioTek-Cytation-5 cell imaging multimodal reader to determine the NADH concentration in the reaction mixture. Samples with significantly higher NADH content than the control group were screened, and further screened by HPLC. Mutants with significantly increased 1L-epi-2-inosose production were sequenced, ultimately yielding recombinant strains containing squalene dehydrogenase mutants with significant effects: E. coli BL21 / pET21a-PksIDH-C261R, E. coli BL21 / pET21a-PksIDH-F322T, and E. coli BL21 / pET21a-PksIDH-C261R / F322T.
[0166] (3) Kinetic parameters of squalinositol dehydrogenase mutant
[0167] Enzyme activity and kinetic data were obtained using a BioTek-Cytation-5 cell imaging multimodal reader at 30°C and pH 7.5. The results are shown in Table 2.
[0168] Table 2: Kinetic parameters and specific enzyme activity of squalinositol dehydrogenase and its mutants
[0169]
[0170] The results showed that the catalytic efficiency k of the mutant E. coli BL21 / pET21a-PksIDH-C261R / F322T for myo-inositol was significantly higher. cat / K m It is 3.2 times that of the wild type.
[0171] Example 3: Preparation of 1 L-epiotensin-2-inositol from muscle inositol using whole-cell catalysis with the squalene dehydrogenase mutant E.coli BL21 / pET21a-PksIDH-C261R / F322T.
[0172] 1. Reaction system:
[0173] Add 20 mM muscle inositol and 20 mM NAD to a 1 mL reaction system. + Whole cells of E. coli BL21 / pET21a-PksIDH-C261R / F322T, at a concentration of 30 g / L, were used in a reaction buffer of 50 mM Tris-HCl (pH 7.5). The reaction was carried out at 30 °C and 200 rpm for 12 h, and samples were taken for high-performance liquid chromatography (HPLC) analysis.
[0174] 2. Optimization of reaction conditions
[0175] (1) Optimal pH
[0176] The optimal reaction pH for the recombinant engineered strain E. coli BL21 / pET21a-PksIDH-C261R / F322T was determined by the yield of product 1L-epio-2-inosaccharide in a reaction system within the pH range of 6.0 to 10.0 (other reaction conditions are the same as in step 1).
[0177] like Figure 8 As shown in Figure A, the recombinant engineered strain E. coli BL21 / pET21a-PksIDH-C261R / F322T showed the highest yield of 1 L-epio-2-inosaccharide, at 43.4%, when reacted in a system at pH 9.5.
[0178] (2) Optimal temperature
[0179] The optimal temperature for the recombinant engineered strain E. coli BL21 / pET21a-PksIDH-C261R / F322T was determined by whole-cell catalysis in a reaction system at pH 9.5 within the range of 20–50 °C, based on the yield of the product 1L-epio-2-inosaccharide (other reaction conditions are the same as in step 1).
[0180] like Figure 8 As shown in B, the recombinant engineered strain E. coli BL21 / pET21a-PksIDH-C261R / F322T showed the highest yield of 1 L-epi-2-inosaccharide, at 47.2%, when reacted at 28°C.
[0181] (3) Optimal cell quantity
[0182] The optimal cell mass for recombinant engineered E. coli BL21 / pET21a-PksIDH-C261R / F322T was determined by whole-cell catalysis in a reaction system with a cell mass range of 10–100 g / L at pH 9.5 and 28°C, using the yield of product 1 L-epio-2-inosaccharide (other reaction conditions are the same as in step 1).
[0183] like Figure 8 As shown in C, when the total amount of recombinant engineered E. coli BL21 / pET21a-PksIDH-C261R / F322T added was 80 g / L, the yield of 1 L-epi-2-inosaccharide was the highest, at 64.4%.
[0184] (4) Optimal substrate amount
[0185] The optimal substrate amount for the recombinant engineered strain E. coli BL21 / pET21a-PksIDH-C261R / F322T was determined by whole-cell catalysis in a reaction system ranging from 1 to 100 mM myoinositol under conditions of pH 9.5, 28°C, and 80 g / L cell density, using the yield of 1 L-epio-2-inositol. NAD+ + The final concentration is the same as the final concentration of the substrate muscle inositol (other reaction conditions are the same as in step 1).
[0186] like Figure 8 As shown in D, the recombinant engineered strain E. coli BL21 / pET21a-PksIDH-C261R / F322T showed the highest yield of 1 L-epi-2-inosaccharide (67.1%) when reacted with 20 mM muscle inositol.
[0187] (5) Optimal reaction time
[0188] The optimal reaction time for the recombinant engineered strain E. coli BL21 / pET21a-PksIDH-C261R / F322T was determined by the yield of 1 L-epio-2-inositol by whole-cell catalysis under the conditions of pH 9.5, 28℃, 80 g / L cells, and 20 mM muscle inositol for 2–24 h (other reaction conditions are the same as in step 1).
[0189] like Figure 8 As shown in E, the recombinant engineered strain E.coli BL21 / pET21a-PksIDH-C261R / F322T showed the highest yield of 1 L-epio-2-inosaccharide, at 70.5%, after 12 h of reaction.
[0190] Example 4: Screening for thermostable muscle inositol dehydrogenase mutants
[0191] The specific steps are as follows:
[0192] 1. Structural analysis of thermostable muscle inositol dehydrogenase
[0193] By performing molecular docking of GtIDH with 1L-epi-2-inosose and the cofactor NADH, the results are as follows: Figure 5 As shown in C, several semi-conserved sites, such as M122, R124, Y173, and F177, located within the substrate-binding region were identified, and virtual mutations were performed on these semi-conserved sites.
[0194] 2. Virtual screening of mutant sites of thermostable muscle inositol dehydrogenase
[0195] By performing virtual saturation mutagenesis on the amino acid residues obtained from the screening in step 1, the results are as follows: Figure 6As shown in B, the binding energies of mutation sites R124 and F177 to the protein molecule show significant changes, proving that this site is a key residue for binding to the substrate 1L-epi-2-inosose. This site was selected as the mutation site for directed evolution.
[0196] 3. Directed evolution of thermostable muscle inositol dehydrogenase mutants
[0197] The mutation hotspots R124 and F177 from step 2 were selected as mutation origins. Then, random mutations were introduced at the corresponding sites by PCR using degenerate primers (NNK-MNN). The degenerate primer (NNK-MNN) sequence is as follows:
[0198] Table 3: Primer design for the mutant gene of thermostable muscle inositol dehydrogenase
[0199]
[0200] The PCR reaction mixture was as follows: 1 μL upstream primer, 1 μL downstream primer, 1 μL template plasmid, 5 μL 2×Primstar, and 2 μL ddH2O. The pre-denaturation temperature was 98℃ for 30 s, the denaturation temperature was 98℃ for 15 s, the annealing temperature was 55℃ for 30 s, and the extension temperature was 72℃ for 80 s.
[0201] (2) The wild-type recombinant expression vector and the recombinant expression vector with random mutations were transformed into E. coli BL21(DE3) competent cells to prepare recombinant expression strains (the synthesis of genes and the construction of recombinant engineered bacteria were completed by Sangon Biotech (Shanghai) Co., Ltd.).
[0202] First, the monoclonal recombinant strains with introduced random mutations were cultured and induced to express the enzyme in 96-well plates, with the wild-type strain as a control (culture conditions were the same as for whole-cell preparation in Example 1). After centrifugation and removal of the supernatant, 1 mL of the reaction mixture (pH 7.5) was added in situ for resuspending. The reaction mixture contained 10 mM NADH and 10 mM 1 L-epi-2-inosose (dissolved in 50 mM Tris-NaCl buffer). After heat treatment at 60 °C for 20 min, the reaction mixture was reacted at 45 °C and 200 rpm for 12 h. After the reaction, the enzyme activity was terminated by heat inactivation of the reaction mixture.
[0203] Subsequently, absorbance was measured at 340 nm using a BioTek-Cytation-5 cell imaging multimodal reader to determine the NADH concentration in the reaction mixture. Samples with significantly lower NADH content than the control group were screened, and then rescreened by HPLC. Mutants with significantly increased epi-inositol production were sequenced, ultimately yielding recombinant strains containing thermostable muscle inositol dehydrogenase mutants: E. coli BL21 / pET28a-GtIDH-F177K, E. coli BL21 / pET28a-GtIDH-F177E, E. coli BL21 / pET28a-GtIDH-F177R, E. coli BL21 / pET28a-GtIDH-F177S, E. coli BL21 / pET28a-GtIDH-R124W, and E. coli BL21 / pET28a-GtIDH-R124C.
[0204] (3) Kinetic parameters of thermostable muscle inositol dehydrogenase mutant
[0205] Kinetic data were obtained using the BioTek-Cytation-5 cell imaging multimodal reader at 45°C and pH 7.5. The results are shown in Table 4.
[0206] Table 4: Kinetic parameters and specific enzyme activity of thermostable muscle inositol dehydrogenase and its mutants
[0207]
[0208] The results showed that the catalytic efficiency k of the mutant E. coli BL21 / pET28a-GtIDH-F177K for 1L-epi-2-inosose was [missing information]. cat / K m It is 1.7 times that of the wild type.
[0209] Example 5: Preparation of epiinositol from 1 L-epio-2-inositol using whole-cell catalysis of a thermostable muscle inositol dehydrogenase mutant E. coli BL21 / pET28a-GtIDH-F177K.
[0210] 1. Reaction system:
[0211] In a 1 mL reaction system, 1 L-epio-2-inosaccharide, 20 mM NADH, and 0.5 mM Zn were added to a final concentration of 20 mM. 2+Whole cells of E. coli BL21 / pET28a-GtIDH-F177K (30 g / L) were used, and the reaction buffer was 50 mM Tris-HCl (pH 7.5). After heat treatment at 60 °C for 20 min, the mixture was reacted at 45 °C and 200 rpm for 12 h. Samples were then taken for high-performance liquid chromatography (HPLC) analysis of substrate and product concentrations.
[0212] 2. Optimization of reaction conditions
[0213] (1) Optimal heat treatment conditions
[0214] The optimal heat treatment conditions for the recombinant engineered strain E. coli BL21 / pET28a-GtIDH-F177K are heat shock at 50–70°C for 10–30 min (specific conditions are as follows). Figure 9 The yield of the product epiinositol was determined by whole-cell catalysis (as shown in A in the figure) (other reaction conditions are the same as in step 1).
[0215] like Figure 9 As shown in Figure A, the recombinant engineered strain E.coli BL21 / pET28a-GtIDH-F177K exhibited the highest yield of epiinositol, at 24.38%, when heat-treated at 65°C for 30 min.
[0216] (2) Optimal pH
[0217] The optimal reaction pH for the recombinant engineered strain E. coli BL21 / pET28a-GtIDH-F177K was determined by whole-cell catalysis in a reaction system within the pH range of 6.0 to 10.0 to achieve the yield of the product epiinositol (after heat treatment at 65°C for 30 min, with other reaction conditions the same as in step 1).
[0218] like Figure 9 As shown in B, the recombinant engineered strain E. coli BL21 / pET28a-GtIDH-F177K exhibited the highest yield of epiinositol, at 25.16%, when reacted in a system with pH 7.5.
[0219] (3) Optimal temperature
[0220] The optimal temperature for the recombinant engineered strain E. coli BL21 / pET28a-GtIDH-F177K was determined by whole-cell catalysis of the product epiinositol in a reaction system at pH 7.5, after heat treatment at 65℃ for 30 min, within the range of 35–70℃ (other reaction conditions were the same as in step 1).
[0221] like Figure 9As shown in C, the recombinant engineered strain E.coli BL21 / pET28a-GtIDH-F177K exhibited the highest yield of epiinositol, at 29.33%, when reacted at 50°C.
[0222] (4) Optimal cell quantity
[0223] The optimal cell mass of recombinant engineered E. coli BL21 / pET28a-GtIDH-F177K was determined by whole-cell catalysis in a reaction system with a cell mass range of 10–100 g / L after heat treatment at pH 7.5 and 65℃ for 30 min, followed by 50℃ (other reaction conditions are the same as in step 1).
[0224] like Figure 9 As shown in D, when the total amount of recombinant engineered E. coli BL21 / pET28a-GtIDH-F177K added was 40 g / L, the yield of epiinositol was the highest, at 36.74%.
[0225] (5) Optimal substrate amount
[0226] The optimal substrate amount for the recombinant engineered strain E. coli BL21 / pET28a-GtIDH-F177K was determined by whole-cell catalysis using the yield of the product epiinositol, following heat treatment at pH 7.5 and 65℃ for 30 min, followed by a reaction system at 50℃ and 40 g / L cell conditions, within the range of 1–100 mM 1 L-epio-2-glycosides. The final NADH concentration was consistent with the final 1 L-epio-2-glycoside concentration of the substrate.
[0227] like Figure 9 As shown in E, the recombinant engineered strain E.coli BL21 / pET28a-GtIDH-F177K exhibited the highest epiinositol yield of 39.71% under the condition of 40 mM 1 L-epio-2-inositol addition.
[0228] (6) Best Zn 2+ Added amount
[0229] The optimal substrate amount for the recombinant engineered strain E. coli BL21 / pET28a-GtIDH-F177K was determined under the following conditions: pH 7.5, heat treatment at 65℃ for 30 min followed by 50℃, 40 g / L cells, 40 mM of 1 L-epio-2-inositol, and 0.1–5 mM Zn. 2+ In reaction systems within the specified range, whole-cell catalysis is determined by the yield of the product epiinositol.
[0230] like Figure 9As shown in F, the recombinant engineered E. coli BL21 / pET28a-GtIDH-F177K was cultured in 1 mM ZnO2. 2+ Under the given addition conditions, the yield of epiinositol was the highest, at 44.25%.
[0231] (7) Optimal reaction time
[0232] The optimal substrate amount for the recombinant engineered strain E. coli BL21 / pET28a-GtIDH-F177K was determined by heat treatment at pH 7.5 and 65℃ for 30 min, followed by 50℃, 40 g / L cells, 40 mM of 1 L-epiotensin, and 1 mM Zn. 2+ The yield of the product epiinositol was determined by whole-cell catalysis under certain conditions for 2–24 h.
[0233] like Figure 9 As shown in G, the recombinant engineered strain E.coli BL21 / pET28a-GtIDH-F177K exhibited the highest yield of epiinositol, at 52.96%, after 14 hours of reaction.
[0234] Example 6: Two-step whole-cell catalytic preparation of epiinositol from muscle inositol
[0235] The specific steps are as follows:
[0236] 1. Preparation of Epiinositol using Wild-Type Enzyme Dual Enzyme
[0237] (1) To a reaction system containing 50 mM Tris-HCl (pH 9.5) buffer, add muscle inositol to a final concentration of 20 mM and NAD+ to a final concentration of 20 mM. + After adding 80 g / L of E. coli BL21 / pET21a-PksIDH whole cells (construction method as in Example 1), the reaction was carried out at 28 °C and 200 rpm for 12 h.
[0238] (2) Add Zn to the system after the reaction in step (1) is completed. 2+ And E. coli BL21 / pET28a-GtIDH whole cells (construction method same as in Example 1), Zn 2+ The final concentration was 1 mM, and the final cell concentration was 40 g / L. The reaction system was heat-shocked at 65 °C for 30 min, then reacted at 50 °C and 200 rpm for 14 h. Samples were taken for high-performance liquid chromatography (HPLC) analysis of the substrate and product concentrations.
[0239] Experimental results showed that in the two-step whole-cell catalytic preparation of epiinositol using squalene dehydrogenase and thermostable muscle inositol dehydrogenase, the total yield of epiinositol was 14.8%, and the yield was 0.53 g / L.
[0240] 2. Preparation of epiinositol from squalene dehydrogenase mutant and thermostable muscle inositol dehydrogenase
[0241] (1) To a reaction system containing 50 mM Tris-HCl (pH 9.5) buffer, add muscle inositol to a final concentration of 20 mM and NAD+ to a final concentration of 20 mM. + After adding 80 g / L of E. coli BL21 / pET21a-PksIDH-C261R / F322T whole cells (construction method as in Example 2), the mixture was reacted at 28 °C and 200 rpm for 12 h.
[0242] (2) Add Zn to the system after the reaction in step (1) is completed. 2+ And E. coli BL21 / pET28a-GtIDH whole cells (construction method same as in Example 1), Zn 2+ The final concentration was 1 mM, and the final cell concentration was 40 g / L. The above reaction system was heat-shocked at 65 °C for 30 min, and then reacted at 50 °C and 200 rpm for 14 h. Samples were then taken for high-performance liquid chromatography (HPLC) analysis.
[0243] Experimental results showed that in the two-step whole-cell catalytic preparation of epiinositol using squalene dehydrogenase mutant and thermostable muscle inositol dehydrogenase, the total yield of epiinositol was 45.2%, and the yield was 1.63 g / L.
[0244] 3. Preparation of epiinositol from squalinositol dehydrogenase mutants and thermostable muscle inositol dehydrogenase mutants.
[0245] (1) To a reaction system containing 50 mM Tris-HCl (pH 9.5) buffer, add muscle inositol to a final concentration of 20 mM and NAD+ to a final concentration of 20 mM. + After adding 80 g / L of E. coli BL21 / pET21a-PksIDH-C261R / F322T whole cells (construction method as in Example 2), the mixture was reacted at 28 °C and 200 rpm for 12 h.
[0246] (2) Add Zn to the reaction system obtained in step (1). 2+ And E. coli BL21 / pET28a-GtIDH-F177K whole cells (construction method same as in Example 4), Zn 2+ The final concentration was 1 mM, and the final cell concentration was 40 g / L. The above reaction system was heat-shocked at 65 °C for 30 min, and then reacted at 50 °C and 200 rpm for 14 h. Samples were then taken for high-performance liquid chromatography (HPLC) analysis.
[0247] Experimental results showed that in the two-step whole-cell catalytic preparation of epiinositol using squalene dehydrogenase mutant and thermostable muscle inositol dehydrogenase mutant, the total yield of epiinositol was 52.6%, and the yield was 1.89 g / L.
[0248] Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Anyone skilled in the art can make various modifications and alterations without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be determined by the claims.
Claims
1. A method for preparing epiinositol, characterized in that, Using a squalinositol dehydrogenase mutant or a genetically engineered bacterium expressing a squalinositol dehydrogenase mutant, catalyzing the synthesis of 1L-epio-2-inosaccharide from muscle inositol; then adding thermostable muscle inositol dehydrogenase or its mutant, or a genetically engineered bacterium expressing thermostable muscle inositol dehydrogenase or its mutant, to catalyze the synthesis of epiinositol from the 1L-epio-2-inosaccharide. The squalinositol dehydrogenase mutant is obtained by mutating cysteine at position 261 of the squalinositol dehydrogenase shown in SEQ ID NO.1 to arginine, and simultaneously mutating phenylalanine at position 322 to threonine; or by mutating phenylalanine at position 322 of the squalinositol dehydrogenase shown in SEQ ID NO.1 to threonine. The heat-resistant muscle inositol dehydrogenase is derived from Laceyella putida , Geobacillus thermoleovorans , Parageobacillus thermoglucosidasius or Marinithermofilum abyssi The thermostable muscle inositol dehydrogenase mutant is obtained by mutating phenylalanine at position 177 of the thermostable muscle inositol dehydrogenase, as shown in SEQ ID NO.2, to lysine or glutamic acid.
2. The preparation method according to claim 1, characterized in that, The reaction system for catalyzing muscle inositol is as follows: the concentration of the substrate muscle inositol is 1~100 mM, and NAD... + The concentration of the bacteria is 1~100 mM, and the amount of genetically engineered bacteria added is 10~100 g / L.
3. The preparation method according to claim 2, characterized in that, The concentration of the substrate muscle inositol was 10-80 mM, and the amount of genetically engineered bacteria added was 30-90 g / L.
4. The preparation method according to claim 3, characterized in that, The concentration of the substrate muscle inositol is 15-60 mM, NAD... + The concentration is 15~60 mM, and the amount of genetically engineered bacteria added is 40~80 g / L; The reaction conditions for catalyzing muscle inositol are: reaction at pH 6.0~10.0 and 20~50℃ for 2~24 h.
5. The preparation method according to claim 4, characterized in that, The reaction conditions for catalyzing muscle inositol are: pH 8.0~9.5, 25~40℃ for 6~14 h.
6. The preparation method according to any one of claims 1 to 5, wherein the reaction system catalyzing the 1L-epio-2-inosaccharide is: the concentration of the substrate 1L-epio-2-inosaccharide is 1~100 mM, and Zn 2+ The amount of added bacteria is 0.1~5 mM, and the amount of added genetically engineered bacteria is 10~100 g / L.
7. The preparation method according to claim 6, characterized in that, The concentration of substrate 1L-epi-2-inositol is 10~80mM, Zn 2+ The addition amount is 0.5~4 mM, and the addition amount of genetically engineered bacteria is 20~80 g / L.
8. The preparation method according to claim 7, characterized in that, The concentration of substrate 1L-epi-2-inositose is 20~60mM, Zn 2+ The amount of added bacteria is 1~3 mM, and the amount of added genetically engineered bacteria is 30~60 g / L; The reaction conditions for catalyzing the 1L-epio-2-inosaccharide are as follows: the genetically engineered bacteria are heat-treated before the reaction is carried out; the heat treatment conditions are as follows: the heat treatment temperature is 50~70℃.
9. The preparation method according to claim 8, characterized in that, The heat treatment temperature is 55~70℃.
10. The preparation method according to claim 8, characterized in that, The heat treatment temperature is 60~65℃.
11. The preparation method according to claim 8, characterized in that, The heat treatment time is 10~30 min.
12. The preparation method according to claim 8, characterized in that, The heat treatment time is 20~30 min; The conditions for reacting the genetically engineered bacteria after heat treatment are: pH 6.0~10.0, 35~70℃ for 2~24h.
13. The preparation method according to claim 8, characterized in that, The reaction is carried out at pH 6.5~8.0 and 40~60℃ for 8~16 hours.
14. The preparation method according to claim 8, characterized in that, The reaction was carried out at pH 7.5 and 50-55℃ for 14-16 h.
15. A squalinositol dehydrogenase mutant, characterized in that, The squalinositol dehydrogenase mutant was obtained by mutating phenylalanine at position 322 of the squalinositol dehydrogenase, as shown in SEQ ID NO.1, to threonine. Alternatively, it can be obtained by mutating cysteine at position 261 of squalinositol dehydrogenase, as shown in SEQ ID NO.1, to arginine, and simultaneously mutating phenylalanine at position 322 to threonine.
16. A thermostable muscle inositol dehydrogenase mutant, characterized in that, The thermostable muscle inositol dehydrogenase mutant is obtained by mutating phenylalanine at position 177 of the thermostable muscle inositol dehydrogenase, as shown in SEQ ID NO.2, to lysine or glutamic acid.
17. A gene encoding the squalinositol dehydrogenase mutant of claim 15 or the thermostable muscle inositol dehydrogenase mutant of claim 16.
18. A recombinant vector carrying the gene of claim 17.
19. A recombinant cell expressing the mutant of claim 15 or 16, or carrying the gene of claim 17, or carrying the recombinant vector of claim 18.
20. The recombinant cell according to claim 19, characterized in that, The recombinant cells use bacteria or fungi as host cells.
21. A method for improving the affinity of squalinositol dehydrogenase for the substrate muscle inositol and its catalytic efficiency, characterized in that, The cysteine at position 261 of the squalene dehydrogenase, as shown in SEQ ID NO.1, is mutated to arginine, and the phenylalanine at position 322 is mutated to threonine. Alternatively, the phenylalanine at position 322 of the squalene dehydrogenase, as shown in SEQ ID NO.1, may be mutated to threonine.
22. A method for improving the affinity and catalytic efficiency of thermostable muscle inositol dehydrogenase for the substrate 1L-epio-2-inosaccharide, characterized in that, The phenylalanine at position 177 of the thermostable muscle inositol dehydrogenase, as shown in SEQ ID NO.2, is mutated to lysine or glutamic acid.
23. The use of the preparation method according to any one of claims 1 to 14, or the mutant according to claim 15 or 16, or the gene according to claim 17, or the recombinant vector according to claim 18, or the recombinant cell according to claim 19 or 20 in the preparation of epiinositol or products containing epiinositol.
Citation Information
Patent Citations
Preparation method of scyllitol
CN110857444A
Recombinant escherichia coli and method for synthesizing scyllo-inositol by using glucose
CN118726219A
